智利某市基于风险年龄的大规模疫苗接种项目后疫苗有效性对减少COVID-19相关住院的比较:观察性研究设计的比较
在智利兰卡瓜市2021年3月1日至8月31日,链接四个数据源开展基于人群的队列、检测阴性(TN)和综合征阴性(SN)病例对照设计,比较SARS-CoV-2疫苗对COVID-19相关住院的有效性。全程接种对比未接种的年龄性别调整疫苗有效性:队列设计67.2(55.7-76.3),TN设计67.8(44.1-81.4),SN设计77.9(70.2-83.8)。结论认为三种设计估计的疫苗有效性趋势不同,SN病例对照设计可能是评估真实世界COVID-19疫苗有效性的高效选择。
要点
- 队列设计疫苗有效性67.2(55.7-76.3),TN设计67.8(44.1-81.4),SN设计77.9(70.2-83.8)。
- 研究链接初级医疗、住院登记、流行病学监测和国家免疫规划四个数据源。
- 作者认为SN病例对照设计可能是评估真实世界COVID-19疫苗有效性的高效选择。
核心结论
- 基于年龄和风险组的COVID-19疫苗接种项目的疫苗有效性在三种观察性研究设计间趋势不同。
- 作者认为SN病例对照设计可能是评估真实世界COVID-19疫苗有效性的高效选择。
研究设计与样本
- 在智利兰卡瓜市2021年3月1日至8月31日开展非匹配的基于人群队列、TN和SN病例对照设计,链接四个数据源。
- 2021年3月1日兰卡瓜市初级医疗系统登记191,505人,其中116,453人符合队列研究纳入标准。
- 研究期间同一地点登记9,471例住院,其中526例为COVID-19病例,108例为TN对照,1,628例为SN对照。
- 为确保未暴露组样本量充足、队列设计随访完成及病例对照设计中接种与住院间有足够时间,疫苗有效性按每个个体比较8周期间估计。
主要发现
- 任何疫苗产品,全程接种对比未接种的年龄性别调整疫苗有效性:队列设计67.2(55.7-76.3)。
- 任何疫苗产品,全程接种对比未接种的年龄性别调整疫苗有效性:TN设计67.8(44.1-81.4)。
- 任何疫苗产品,全程接种对比未接种的年龄性别调整疫苗有效性:SN设计77.9(70.2-83.8)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Case-control studies involving test-negative (TN) and syndrome-negative (SN) controls are reliable for evaluating influenza and rotavirus vaccine effectiveness (VE) during a random vaccination process. However, there is no empirical evidence regarding the impact in real-world mass vaccination campaigns against SARS-CoV-2 using TN and SN controls. OBJECTIVE: To compare in the same population the effectiveness of SARS-CoV-2 vaccination on COVID-19-related hospitalization rates across a cohort design, TN and SN designs. METHOD: We conducted an unmatched population-based cohort, TN and SN case-control designs linking data from four data sources (public primary healthcare system, hospitalization registers, epidemiological surveillance systems and the national immunization program) in a Chilean municipality (Rancagua) between March 1, 2021 and August 31, 2021. The outcome was COVID-19-related hospitalization. To ensure sufficient sample size in the unexposed group, completion of follow-up in the cohort design, and sufficient time between vaccination and hospitalization in the case-control design, VE was estimated comparing 8-week periods for each individual. RESULTS: Among the 191,505 individuals registered in the primary healthcare system of Rancagua in Chile on March 1, 2021; 116,453 met the cohort study's inclusion criteria. Of the 9,471 hospitalizations registered during the study period in the same place, 526 were COVID-19 cases, 108 were TN controls, and 1,628 were SN controls. For any vaccine product, the age- and sex-adjusted vaccine effectiveness comparing fully and nonvaccinated individuals was 67.2 (55.7-76.3) in the cohort design, whereas it was 67.8 (44.1-81.4) and 77.9 (70.2-83.8) in the TN and SN control designs, respectively. CONCLUSION: The VE of a COVID-19 vaccination program based on age and risk groups tended to differ across the three observational study designs. The SN case-control design may be an efficient option for evaluating COVID-19 VE in real-world settings.
引用
- Urquidi C, Sepúlveda-Peñaloza A, Valenzuela MT, et al. Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs. Vaccine. 2024. PMID: 38749822. doi:10.1016/j.vaccine.2024.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。